As many of you know, our beautiful Welsh dragon, Tassia Haines sadly died in March 2024. Tass touched thousands of lives across the globe, with her informed, honest, humbling, passionate
“It shouldn’t be this hard”. That was a comment on my Twitter thread…
Clinical trials are essential for testing new treatments for metastatic breast cancer (MBC). For patients, they represent hope – the chance to get access to a new potential treatment before
In our recent Metastatic May campaign, the theme was ‘The Cost of Living’
In our recent Metastatic May campaign, the theme was ‘The Cost of Living’. Living with metastatic breast cancer affects personal finances, careers, and overall income. But we also explored the
Treatement lines and herceptin for HER2+ metastatic breast cancer
Any patient with metastatic breast cancer (MBC) will be familiar with the concept of ‘treatment lines’. Unlike primary breast cancer, where you undergo chemotherapy for a fixed time period, after
13th October – metastatic (secondary) breast cancer day – redefining MBC…
A friend a few weeks ago recently joined the statistic of 31 women that die every day of metastatic breast cancer, and we just hear the same words and comments.
Breast cancer patients denied life-extending drug by NICE
A cancer drug which received standing ovation from the Global Medical Community is being withheld from NHS breast cancer patients. METUPUK are devastated by NICE decision not to recommend the drug
METUPUK update
METUPUK members have done amazing things in the last two years and continue to do so. Here is an update on the last two months: Founder Jo Taylor was due
My Journey to Alpelisib – Asha Umrawsingh
Asha died in March this year. She wrote this blog explaining the problems that she experienced trying to access a drug that she was ineligible for because she fell outside of the
Drugs drugs everywhere, can you access ones that work? Kirstin Spencer
Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline